ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Intergalactic Therapeutics has launched with $75 million in series A financing to develop a nonviral gene therapy. Most gene therapies rely on viral vectors to deliver DNA into the body, but Intergalactic plans to use a pulsed electrical field to temporarily disrupt cell membranes and allow its “covalently closed and circular DNA” molecules to slip into cells. The approach is designed to be nonimmunogenic and redoseable, with an initial focus on cancer, eye diseases, and respiratory conditions.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter